These findings validate a misregulation of mTOR signaling in dystrophic dystroglycanopathy skeletal muscle and suggest that such signaling molecules may be relevant targets to delay and/or reduce disease burden in dystrophic patients. This evidence concerns the gene MTOR and neuromuscular disease caused by qualitative or quantitative defects of alpha-dystroglycan.